Tags

Type your tag names separated by a space and hit enter

Concurrent chemoradiotherapy with helical tomotherapy for oropharyngeal cancer: a preliminary result.
Int J Radiat Oncol Biol Phys. 2010 Jul 01; 77(3):715-21.IJ

Abstract

PURPOSE

To review the experience with and evaluate the treatment plan for helical tomotherapy for the treatment of oropharyngeal cancer.

METHODS AND MATERIALS

Between November 1, 2006 and January 31, 2009, 10 histologically confirmed oropharyngeal cancer patients were enrolled. All patients received definitive concurrent chemoradiation with helical tomotherapy. The prescription dose to the gross tumor planning target volume, the high-risk subclinical area, and the low-risk subclinical area was 70 Gy, 63 Gy, and 56 Gy, respectively. During radiotherapy, all patients were treated with cisplatin, 30 mg/m(2), plus 5-fluorouracil (425 mg/m(2))/leucovorin (30 mg/m(2)) intravenously weekly. Toxicity of treatment was scored according to the Common Terminology Criteria for Adverse Events, version 3.0. Several parameters, including maximal or median dose to critical organs, uniformity index, and conformal index, were evaluated from dose-volume histograms.

RESULTS

The mean survival was 18 months (range, 7-22 months). The actuarial overall survival, disease-free survival, locoregional control, and distant metastasis-free rates at 18 months were 67%, 70%, 80%, and 100%, respectively. The average for uniformity index and conformal index was 1.05 and 1.26, respectively. The mean of median dose for right side and left side parotid glands was 23.5 and 23.9 Gy, respectively. No Grade 3 toxicity for dermatitis and body weight loss and only one instance of Grade 3 mucositis were noted.

CONCLUSION

Helical tomotherapy achieved encouraging clinical outcomes in patients with oropharyngeal carcinoma. Treatment toxicity was acceptable, even in the setting of concurrent chemotherapy. Long-term follow-up is needed to confirm these preliminary findings.

Authors+Show Affiliations

Department of Radiation Oncology, Far Eastern Memorial Hospital, Taipei, Taiwan.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Evaluation Study
Journal Article

Language

eng

PubMed ID

19879069

Citation

Shueng, Pei-Wei, et al. "Concurrent Chemoradiotherapy With Helical Tomotherapy for Oropharyngeal Cancer: a Preliminary Result." International Journal of Radiation Oncology, Biology, Physics, vol. 77, no. 3, 2010, pp. 715-21.
Shueng PW, Wu LJ, Chen SY, et al. Concurrent chemoradiotherapy with helical tomotherapy for oropharyngeal cancer: a preliminary result. Int J Radiat Oncol Biol Phys. 2010;77(3):715-21.
Shueng, P. W., Wu, L. J., Chen, S. Y., Hsiao, C. H., Tien, H. J., Cheng, P. W., Kuo, Y. S., Chen, Y. J., Chen, C. A., Hsieh, P. Y., & Hsieh, C. H. (2010). Concurrent chemoradiotherapy with helical tomotherapy for oropharyngeal cancer: a preliminary result. International Journal of Radiation Oncology, Biology, Physics, 77(3), 715-21. https://doi.org/10.1016/j.ijrobp.2009.06.026
Shueng PW, et al. Concurrent Chemoradiotherapy With Helical Tomotherapy for Oropharyngeal Cancer: a Preliminary Result. Int J Radiat Oncol Biol Phys. 2010 Jul 1;77(3):715-21. PubMed PMID: 19879069.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Concurrent chemoradiotherapy with helical tomotherapy for oropharyngeal cancer: a preliminary result. AU - Shueng,Pei-Wei, AU - Wu,Le-Jung, AU - Chen,Shiou-Yi, AU - Hsiao,Chi-Huang, AU - Tien,Hui-Ju, AU - Cheng,Po-Wen, AU - Kuo,Ying-Shiung, AU - Chen,Yu-Jen, AU - Chen,Chien-An, AU - Hsieh,Pei-Ying, AU - Hsieh,Chen-Hsi, Y1 - 2009/10/29/ PY - 2009/02/26/received PY - 2009/05/30/revised PY - 2009/06/01/accepted PY - 2009/11/3/entrez PY - 2009/11/3/pubmed PY - 2010/6/15/medline SP - 715 EP - 21 JF - International journal of radiation oncology, biology, physics JO - Int J Radiat Oncol Biol Phys VL - 77 IS - 3 N2 - PURPOSE: To review the experience with and evaluate the treatment plan for helical tomotherapy for the treatment of oropharyngeal cancer. METHODS AND MATERIALS: Between November 1, 2006 and January 31, 2009, 10 histologically confirmed oropharyngeal cancer patients were enrolled. All patients received definitive concurrent chemoradiation with helical tomotherapy. The prescription dose to the gross tumor planning target volume, the high-risk subclinical area, and the low-risk subclinical area was 70 Gy, 63 Gy, and 56 Gy, respectively. During radiotherapy, all patients were treated with cisplatin, 30 mg/m(2), plus 5-fluorouracil (425 mg/m(2))/leucovorin (30 mg/m(2)) intravenously weekly. Toxicity of treatment was scored according to the Common Terminology Criteria for Adverse Events, version 3.0. Several parameters, including maximal or median dose to critical organs, uniformity index, and conformal index, were evaluated from dose-volume histograms. RESULTS: The mean survival was 18 months (range, 7-22 months). The actuarial overall survival, disease-free survival, locoregional control, and distant metastasis-free rates at 18 months were 67%, 70%, 80%, and 100%, respectively. The average for uniformity index and conformal index was 1.05 and 1.26, respectively. The mean of median dose for right side and left side parotid glands was 23.5 and 23.9 Gy, respectively. No Grade 3 toxicity for dermatitis and body weight loss and only one instance of Grade 3 mucositis were noted. CONCLUSION: Helical tomotherapy achieved encouraging clinical outcomes in patients with oropharyngeal carcinoma. Treatment toxicity was acceptable, even in the setting of concurrent chemotherapy. Long-term follow-up is needed to confirm these preliminary findings. SN - 1879-355X UR - https://www.unboundmedicine.com/medline/citation/19879069/Concurrent_chemoradiotherapy_with_helical_tomotherapy_for_oropharyngeal_cancer:_a_preliminary_result_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0360-3016(09)00935-3 DB - PRIME DP - Unbound Medicine ER -